Friday, October 21, 2022 12:21:21 PM
Biohaven Shares Hit 52-Week High After Public Offering Prices
10:40 am ET October 21, 2022 (Dow Jones) Print
By Chris Wack
Biohaven Ltd. shares were up 17% to $13.98 Friday after the biopharmaceutical company said it priced a public offering of 25 million common shares at $10.50 each.
The stock hit a 52-week high of $15.33 earlier in the session.
The company has granted the underwriters a 30-day option to buy up to an additional 3.75 million shares.
The offering is expected to close on Tuesday, subject to the satisfaction of customary closing conditions.
Biohaven said it intends to use the proceeds received from the offering for general corporate purposes.
10:40 am ET October 21, 2022 (Dow Jones) Print
By Chris Wack
Biohaven Ltd. shares were up 17% to $13.98 Friday after the biopharmaceutical company said it priced a public offering of 25 million common shares at $10.50 each.
The stock hit a 52-week high of $15.33 earlier in the session.
The company has granted the underwriters a 30-day option to buy up to an additional 3.75 million shares.
The offering is expected to close on Tuesday, subject to the satisfaction of customary closing conditions.
Biohaven said it intends to use the proceeds received from the offering for general corporate purposes.
New York Yankees and Duke Basketball
Recent BHVN News
- Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy • PR Newswire (US) • 05/27/2026 11:30:00 AM
- Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile • PR Newswire (US) • 05/26/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:17:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/04/2026 09:07:27 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/04/2026 08:23:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 08:07:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:06:01 PM
- Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results • PR Newswire (US) • 05/04/2026 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:01:42 PM
- Biohaven Shares Edge Higher After Completing Enrollment in Obesity Drug Trial • IH Market News • 03/19/2026 02:12:23 PM
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment • PR Newswire (US) • 03/19/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/13/2026 08:57:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:54:52 PM
- uniQure shares jump 36% after news of FDA gene therapy chief’s departure • IH Market News • 03/09/2026 02:14:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 09:32:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/02/2026 09:30:08 PM
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results • PR Newswire (US) • 03/02/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 04:19:08 PM
- Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/12/2026 04:15:00 PM
- Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 • PR Newswire (US) • 01/07/2026 12:00:00 PM
- Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder • PR Newswire (US) • 12/24/2025 06:00:00 PM
- Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress • PR Newswire (US) • 12/11/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:27:36 PM
- Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M • PR Newswire (US) • 11/13/2025 09:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/13/2025 12:09:09 PM
